Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

BACKGROUND: Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, including the fully humanized monoclonal antibody (IgG2Δa) fremanezumab, have demonstrated safety and efficacy for migraine prevention. Clinical trials include responders and nonresponders; efficacy outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Silberstein, Stephen D., Cohen, Joshua M., Yang, Ronghua, Gandhi, Sanjay K., Du, Evelyn, Jann, Adelene E., Marmura, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792179/
https://www.ncbi.nlm.nih.gov/pubmed/33413075
http://dx.doi.org/10.1186/s10194-020-01212-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792179/
https://www.ncbi.nlm.nih.gov/pubmed/33413075
http://dx.doi.org/10.1186/s10194-020-01212-4

Ejemplares similares